PCRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PCRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-04-27), Pacira BioSciences's current share price is $26.33. Pacira BioSciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $10.78. Pacira BioSciences's Cyclically Adjusted PS Ratio for today is 2.44.
The historical rank and industry rank for Pacira BioSciences's Cyclically Adjusted PS Ratio or its related term are showing as below:
During the past years, Pacira BioSciences's highest Cyclically Adjusted PS Ratio was 12.28. The lowest was 2.37. And the median was 5.59.
PCRX's Cyclically Adjusted PS Ratio is ranked worse thanThe Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Pacira BioSciences's adjusted revenue per share data for the three months ended in Dec. 2023 was $2.631. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $10.78 for the trailing ten years ended in Dec. 2023.
The historical data trend for Pacira BioSciences's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacira BioSciences Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Cyclically Adjusted PS Ratio | Get a 7-Day Free Trial | 4.05 | 4.08 | 3.87 | 2.87 | 3.13 |
For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Pacira BioSciences's Cyclically Adjusted PS Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Pacira BioSciences's Cyclically Adjusted PS Ratio for today is calculated as
Cyclically Adjusted PS Ratio | = | Share Price | / | Cyclically Adjusted Revenue per Share |
= | 26.33 | / | 10.78 | |
= | 2.44 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacira BioSciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:
For example, Pacira BioSciences's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Dec. 2023 (Change) | * | Current CPI (Dec. 2023) |
= | 2.631 | / | 129.4194 | * | 129.4194 | |
= | 2.631 |
Current CPI (Dec. 2023) = 129.4194.
Pacira BioSciences Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201403 | 1.088 | 99.695 | 1.412 |
201406 | 1.330 | 100.560 | 1.712 |
201409 | 1.448 | 100.428 | 1.866 |
201412 | 1.713 | 99.070 | 2.238 |
201503 | 1.396 | 99.621 | 1.814 |
201506 | 1.427 | 100.684 | 1.834 |
201509 | 1.516 | 100.392 | 1.954 |
201512 | 1.693 | 99.792 | 2.196 |
201603 | 1.769 | 100.470 | 2.279 |
201606 | 1.873 | 101.688 | 2.384 |
201609 | 1.832 | 101.861 | 2.328 |
201612 | 1.948 | 101.863 | 2.475 |
201703 | 1.823 | 102.862 | 2.294 |
201706 | 1.766 | 103.349 | 2.211 |
201709 | 1.664 | 104.136 | 2.068 |
201712 | 1.948 | 104.011 | 2.424 |
201803 | 1.833 | 105.290 | 2.253 |
201806 | 2.017 | 106.317 | 2.455 |
201809 | 2.036 | 106.507 | 2.474 |
201812 | 2.312 | 105.998 | 2.823 |
201903 | 2.214 | 107.251 | 2.672 |
201906 | 2.423 | 108.070 | 2.902 |
201909 | 2.514 | 108.329 | 3.003 |
201912 | 2.930 | 108.420 | 3.497 |
202003 | 2.470 | 108.902 | 2.935 |
202006 | 1.788 | 108.767 | 2.127 |
202009 | 2.654 | 109.815 | 3.128 |
202012 | 2.928 | 109.897 | 3.448 |
202103 | 2.589 | 111.754 | 2.998 |
202106 | 2.974 | 114.631 | 3.358 |
202109 | 2.809 | 115.734 | 3.141 |
202112 | 3.499 | 117.630 | 3.850 |
202203 | 3.402 | 121.301 | 3.630 |
202206 | 3.228 | 125.017 | 3.342 |
202209 | 3.654 | 125.227 | 3.776 |
202212 | 3.744 | 125.222 | 3.870 |
202303 | 3.490 | 127.348 | 3.547 |
202306 | 3.256 | 128.729 | 3.273 |
202309 | 3.148 | 129.860 | 3.137 |
202312 | 2.631 | 129.419 | 2.631 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Thank you for viewing the detailed overview of Pacira BioSciences's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Marcelo Bigal | director | C/O PACIRA BIOSCIENCES, INC., 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA FL 33609 |
Abraham Ceesay | director | C/O SCPHARMACEUTICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01830 |
Alethia Young | director | C/O GRAPHITE BIO, INC., 201 HASKINS WAY, SUITE 210, SOUTH SAN FRANCISCO CA 94080 |
Michael J. Yang | director | C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130 |
Roy Winston | officer: Chief Clinical Officer | C/O PACIRA BIOSCIENCES, INC,, 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA FL 33609 |
Lauren Bullaro Riker | officer: Executive Director, Accounting | C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, PARSIPPANY NJ 07054 |
Kristen Marie Williams | officer: CAO and General Counsel | C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054 |
Mark A. Kronenfeld | director | C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 100, PARSIPPANY NJ 07054 |
Daryl Gaugler | officer: Chief Operating Officer | C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054 |
Reinhart Charles A. Iii | officer: Chief Financial Officer | C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054 |
Ellis Ronald J. Jr. | officer: Chief Strategy Officer | C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355 |
Max Reinhardt | officer: President | C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054 |
David M Stack | director, officer: President and CEO | THE MEDICINES CO, 8 CAMPUS DRIVE, PARSIPPANY NJ 07054 |
Dennis Mcloughlin | officer: Chief Commercial Officer | C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054 |
Jonathan Slonin | officer: Chief Clinical Officer | C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054 |
From GuruFocus
By Value_Insider Value_Insider • 11-08-2022
By sperokesalga sperokesalga • 04-20-2023
By Marketwired • 07-26-2023
By sperokesalga sperokesalga • 05-31-2023
By sperokesalga sperokesalga • 03-27-2023
By sperokesalga sperokesalga • 03-22-2023
By PRNewswire PRNewswire • 11-17-2022
By Marketwired • 10-02-2023
By sperokesalga sperokesalga • 04-19-2023
By Marketwired • 11-07-2023